Trial · NCT07451652
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
NCT07451652, Phase 2, Recruiting, Hospital Universitario Dr. Jose E. Gonzalez
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Low Dose Epcoritamab Plus GemOx in R/R DLBCL. Trials, record NCT07451652. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07451652
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Low Dose Epcoritamab Plus GemOx in R/R DLBCL
- NCT number
- NCT07451652
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Conditions
- Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Interventions
- Epcoritamab, Gemcitabine (1000 mg/m2), Oxaliplatin
- First posted
- 2026-03-05
- Last updated
- 2026-04-01
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Determine ORR and CR after GemOx plus low-dose Epcoritamab | From enrollment to the end of treatment at 14 weeks | Determine ORR and CR after 3 cycles of GemOx plus low-dose Epcoritamab based on PET-CT |
| Secondary | Establish feasibility | From enrollment up to day 29 | Determine the number of subjects that complete the first cycle without need for hospitalization |
| Secondary | Describe cytokine release syndrome incidence | From day 1 up to day 29 | Describe the number of subjects who develop grade 2-4 cytokine release syndrome during the first cycle of treatment |
| Secondary | Describe immune effector cell- associated neurotoxicity syndrome incidence | From day 1 up to week 10 | Describe the number of subjects that develop immune effector cell-associated neurotoxicity syndrome |
| Secondary | Describe adverse events | From day 1 up to week 10 | Describe the number of subjects that develop any adverse events |
| Secondary | Determine number of patients that follow through with transplant | From day one up through study completion, an average of 1 year | Determine the number of patients that go through with stem cell transplant after finishing 3 cycles of Epcoritamab + GemOx |
| Secondary | Duration of response | From week 18 through study completion, an average of 1 year | Determine the duration of response |
| Secondary | Progression free survival | From week 18 up to six and twelve months | Report the subjects´ progression free survival |
| Secondary | Overall survival | From day 1 to twelve months | Report the overall survival |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07451652
GET https://conductscience.org/api/trials/v1/NCT07451652/registered